Allo-SCT using BU, CY and melphalan for children with AML in second CR

Bone Marrow Transplantation

Volumn 48, Issue 5, 2013, Pages 651-656

  Beier, R ^a   Albert, M H ^b   Bader, P ^c   Borkhardt, A ^d   Creutzig, U ^a   Eyrich, M ^e   Ehlert, K ^f   Gruhn, B ^g   Greil, J ^h   Handgretinger, R ⁱ   Holter, W ^j   Klingebiel, T ^c   Kremens, B ^k   Lang, P ⁱ   Mauz Korholz C ^l   Meisel, R ^d   Muller I ^m   Peters, C ⁿ   Reinhardt, D ^a   Sedlacek, P ^o   Schulz, A ^p   Schuster, F R ^d   Schrauder, A ^q   Strahm, B ^r   Sykora, K W ^a   Wossmann W ^s   Zimmermann, M ^a   Sauer, M G ^a   more..

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f UNIVERSITY OF MÜNSTER   (Germany)

^g FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ UNIVERSITY OF TÜBINGEN   (Germany)

^j UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^k UNIVERSITY OF DUISBURG ESSEN   (Germany)

^l MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^m UNIVERSITY OF HAMBURG   (Germany)

ⁿ ST ANNA CHILDREN S HOSPITAL   (Austria)

^o UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^p UNIVERSITY OF ULM   (Germany)

^q UNIVERSITY OF KIEL   (Germany)

^r UNIVERSITY OF FREIBURG   (Germany)

^s JUSTUS LIEBIG UNIVERSITY   (Germany)

more..

Author keywords

AML; BU; children; CR2; CY; melphalan

Indexed keywords

BUSULFAN; CYCLOSPORIN A; CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER REGISTRY; CANCER REGRESSION; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; FEMALE; GRAFT FAILURE; HUMAN; INTERPHASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SEPSIS; SIBLING; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MELPHALAN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING;

EID: 84877666383     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.204     Document Type: Article

References (26)

1. Klusmann JH, Reinhardt D, Zimmermann M, Kremens B, Vormoor J, Dworzak M et al. The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. Haematologica 2012; 97: 21-29.
2. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002; 118: 385-400.
3. Wells RJ, Adams MT, Alonzo TA, Arceci RJ, Buckley J, Buxton AB et al. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. J Clin Oncol 2003; 21: 2940-2947.
4. Aladjidi N, Auvrignon A, Leblanc T, Perel Y, Benard A, Bordigoni P et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J ClinOncol 2003; 21: 4377-4385.
5. Abrahamsson J, Clausen N, Gustafsson G, Hovi L, Jonmundsson G, Zeller B et al. Improved outcome after relapse in children with acute myeloid leukaemia. Br J Haematol 2007; 136: 229-236.
6. Sander A, Zimmermann M, Dworzak M, Fleischhack G, von Neuhoff C, Reinhardt D et al. Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia 2010; 24: 1422-1428.
7. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
8. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956.
9. Michel G, Gluckman E, Esperou-Bourdeau H, Reiffers J, Pico JL, Bordigoni P et al. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation-a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 1994; 12: 1217-1222.
10. Pession ArC, Putti MC, Masetti R, Casale F, Fagioli F, Nigro LL et al. Results of the AIEOP AML 2002/01 study for treatment of children with acute myeloid leukemia. Blood [Abstract] 2009; 114: 13.
11. Strahm B, Nollke P, Zecca M, Korthof ET, Bierings M, Furlan I et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. Leukemia 2011; 25: 455-462.
12. Locatelli F, Pession A, Bonetti F, Maserati E, Prete L, Pedrazzoli P et al. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes. Leukemia 1994; 8: 844-849.
13. Dimopoulos MA, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S et al. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 1993; 82: 2324-2328.
14. Przepiorka D, Nath R, Ippoliti C, Mehra R, Hagemeister F, Diener K et al. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. Leuk Lymphoma 1995; 17: 427-433.
15. Kroger N, Zabelina T, Sonnenberg S, Kruger W, Renges H, Stute N et al. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia. Bone Marrow Transplant 2000; 26: 711-716.
16. Naik S, Wong R, Arai S, Brown J, Laport G, Lowsky R et al. Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. Bone Marrow Transplant 2011; 46: 192-199.
17. Phillips GL, Shepherd JD, Barnett MJ, Lansdorp PM, Klingemann HG, Spinelli JJ et al. Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy. J Clin Oncol 1991; 9: 1880-1888.
18. Corringham R, Gilmore M, Prentice HG, Boesen E. High-dose melphalan with autologous bone marrow transplant. Treatment of poor prognosis tumors. Cancer 1983; 52: 1783-1787.
19. Wolff SN, Herzig RH, Fay JW, LeMaistre CF, Brown RA, Frei-Lahr D et al. High-dose N,N0,N0-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies. Semin Oncol 1990; 17(1 Suppl 3): 2-6.
20. Wolff SN, Fer MF, McKay CM, Hande KR, Hainsworth JD, Greco FA. High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study. J Clin Oncol 1983; 1: 701-705.
21. Bishop JF, Lowenthal RM, Joshua D, Matthews JP, Todd D, Cobcroft R et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood 1990; 75: 27-32.
22. Locatelli F, Zecca M, Messina C, Rondelli R, Lanino E, Sacchi N et al. Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors. Leukemia 2002; 16: 2228-2237.
23. Anderson LW, Chen TL, Colvin OM, Grochow LB, Collins JM, Kennedy MJ et al. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy. Clin Cancer Res 1996; 2: 1481-1487.
24. Hassan M, Ljungman P, Ringden O, Hassan Z, Oberg G, Nilsson C et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000; 25: 915-924.
25. Ryu SG, Lee JH, Choi SJ, Lee YS, Seol M, Hur EH et al. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007; 13: 1095-105.
26. Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Nishihori T, Field T et al. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol 2010; 3: 36.